| 61.11 3.07 (5.29%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 71.58  |
1-year : | 83.61 |
| Resists | First : | 61.29 |
Second : | 71.58 |
| Pivot price | 53.94 |
|||
| Supports | First : | 52.73 |
Second : | 47.45 |
| MAs | MA(5) : | 56.17 |
MA(20) : | 53.29 |
| MA(100) : | 43.47 |
MA(250) : | 30.51 |
|
| MACD | MACD : | 2.5 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 88.4 |
D(3) : | 79.1 |
| RSI | RSI(14): 74.9 |
|||
| 52-week | High : | 61.29 | Low : | 14.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ELVN ] has closed Bollinger Bands are 0.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 61.3 - 61.51 | 61.51 - 61.7 |
| Low: | 56.95 - 57.21 | 57.21 - 57.46 |
| Close: | 60.67 - 61.06 | 61.06 - 61.41 |
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Mon, 03 Aug 2026
Enliven Therapeutics stock hits 52-week high at $55.87 - Investing.com
Sat, 01 Aug 2026
Price to book forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Sun, 26 Jul 2026
Enliven Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELVN - TradingView
Tue, 21 Jul 2026
Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise - Stock Titan
Sat, 13 Jun 2026
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial - finance.yahoo.com
Thu, 11 Jun 2026
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 90.3 (%) |
| Shares Short | 8,650 (K) |
| Shares Short P.Month | 5,430 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.9 % |
| Return on Equity (ttm) | -26.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -37.27 |
| PEG Ratio | 0 |
| Price to Book value | 8.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -66.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|